[1] Weinstein, M.; Zeckhauser, R. J. Public Economics. 1973, 2, 147-157.
[2] Health Economic Glossary. This article can be found online at http://www.healtheconomics.nl/W/Cost-effectiveness_ threshold
[3] Towse, A.; Pritchard, C. Dose Nice have a threshold? An external view, in Cost-effectiveness Thresholds: Economic and Ethical Issues (Towse, A.; Pritchard, C.; Devlin, N.). London: BSC Print Ltd. 2002, 25-37.
[4] NICE. Briefing paper for the Methods Working Party on the Cost Effectiveness Threshold. This article can be found online at http://www.nice.org.uk/TAMethodsReview
[5] Devlin, N.; Parkin, D. Health Econ. 2004, 13, 437-452.
[6] Chambers, D.J.; Neumann, J.P.; Buxton, M.J. Med. Decis. Making. 2010, 30, 14-27.
[7] McCabe, C.; Claxton, K.; Culyer, A.J. Pharmacoeconomics. 2008, 26, 733-744.
[8] Loomes, G. Valuing life years and QALYs: transferability and convertibility of values across the UK public sector, in Cost-effectiveness Thresholds: Economic and Ethical Issues (Towse, A.; Pritchard, C.; Devlin, N.). London: BSC Print Ltd. 2002, 25-37.
[9] Sloan, F.A. Valuing Health Care. Cambridge University Press. 1995, 108.
[10] Dowie, J. Health Econ. 2004, 13, 453-459.
[11] Williams, A. What could be nicer than NICE? London: Office of Health Economics. 2004, 35.
[12] World Health Organization (WHO), WHO-CHOICE. This article can be found online at http://www.who.int/choice/costs/CERthresholds/en/index.html
[13] Buxton, M. Ispor Connections. 2007, 8, 9-11.
[14] Grosse, S.D. Pharmacoeconomics Outcomes Res. 2008, 8, 165-178.
[15] Weinstein, M.C.; Torrance, G.; McGuire, A. Value Health. 2009, 12, 364-372.
[16] Birch, S.; Gafni, A. Health Policy. 2003, 64, 207-219.